Modality
Multispecific
MOA
BETi
Target
BTK
Pathway
Wnt
DMD
Development Pipeline
Preclinical
~Dec 2012
→ ~Mar 2014
Phase 1
~Jun 2014
→ ~Sep 2015
Phase 2
~Dec 2015
→ ~Mar 2017
Phase 3
~Jun 2017
→ ~Sep 2018
NDA/BLA
~Dec 2018
→ ~Mar 2020
Approved
Jun 2020
→ Aug 2028
ApprovedCurrent
NCT03558847
134 pts·DMD
2021-04→2026-05·Not yet recruiting
NCT07647735
1,994 pts·DMD
2020-06→2028-08·Terminated
2,128 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2026-05-151mo awayPh3 Readout· DMD
2028-08-262.4y awayPh3 Readout· DMD
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Termina…
Approved
Not yet…
Catalysts
Ph3 Readout
2026-05-15 · 1mo away
DMD
Ph3 Readout
2028-08-26 · 2.4y away
DMD
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03558847 | Approved | DMD | Not yet recr... | 134 | PASI75 |
| NCT07647735 | Approved | DMD | Terminated | 1994 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| COR-9456 | Corcept | Preclinical | TIGIT |